Bibliography
- CAVERO I, CRUMB W: Moving towards better predictors of drug-induced Torsades de Pointes. 2 – 3 November 2005, Crystal City, Virginia, USA. Expert Opin. Drug Saf. (2006) 5(3):335-340.
- LAWRENCE CL, BRIDGLAND-TAYLOR MH, POLLARD CE, HAMMOND TG, VALENTIN J-P: A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes. Br. J. Pharmacol. (2006) 149(7):845-860.
- FITZGERALD GA: Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics. Nat. Rev. Drug Discov. (2005) 4(10):815-818.
- HOLZGREFE HH, CAVERO I, BUCHANAN LV, GILL MW, DURHAM SK: Application of a probabilistic method for the determination of drug-induced QT-prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin. J. Pharmacol. Toxicol. Meth. (2006) (In Press).
- CAVERO I, CRUMB W: Safety Pharmacology Society: 5th Annual Meeting. 27 – 29 September, 2005, Mannheim, Germany. Expert Opin. Drug Saf. (2006) 5(1):181-185.
Websites
- http://www.ich.org/LOB/media/MEDIA504.pdfSafety Pharmacology studies for human pharmaceuticals. S7A. (2000).
- http://www.ich.org/LOB/media/MEDIA2192.pdfThe non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. S7B (2000).
- http://www.emea.europa.eu/pdfs/human/swp/9422704en.pdfGuideline on the non-clinical investigation of the dependence potential of medicinal products. (2006).
- http://www.fda.gov/cder/guidance/7086fnl. pdfGuidance for industry, investigators and reviewers. Exploratory IND studies. (2006).
- http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdfChallenge and opportunity on the critical path to new medical products (2004).
- http://www.emea.europa.eu/pdfs/general/direct/directory/3416303enF.pdfThe European Medicines Agency road map to 2010: preparing the ground for the future. (2005).